Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM: A 24-Week, Multicentre, Randomized, Parallel, Interventional, Non-inferiority, Open-label Study

NCT06327815 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06327815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06327815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM: A 24-Week, Multicentre, Randomized, Parallel, Interventional, Non-inferiority, Open-label Study
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
March 15, 2024
Completion date
June 30, 2025
Enrollment
633 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus (t2dm)